{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T06:57:14Z","timestamp":1768028234467,"version":"3.49.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.ahj.2004.03.042","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T10:18:09Z","timestamp":1092392289000},"page":"243-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Slowing the progression of diabetic nephropathy and its cardiovascular consequences"],"prefix":"10.1016","volume":"148","author":[{"given":"Peter A.","family":"McCullough","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"William F.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preston S.","family":"Klassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Califf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2004.03.042_BIB1","doi-asserted-by":"crossref","unstructured":"Bretzel RG. Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens 1997;10(9 Pt 2):208\u201317S","DOI":"10.1016\/S0895-7061(97)00155-6"},{"key":"10.1016\/j.ahj.2004.03.042_BIB2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0272-6386(99)70442-7","article-title":"Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE)","volume":"33","author":"Keane","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2004.03.042_BIB3","doi-asserted-by":"crossref","unstructured":"Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 2002;15(10 Pt 2):123\u20138S","DOI":"10.1016\/S0895-7061(02)03007-8"},{"key":"10.1016\/j.ahj.2004.03.042_BIB4","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2337\/diacare.23.9.1278","article-title":"Diabetes trends in the US: 1990\u20131998","volume":"23","author":"Mokdad","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2004.03.042_BIB5","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/oxfordjournals.aje.a010167","article-title":"Weight gain continues in the 1990s","volume":"151","author":"Lewis","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ahj.2004.03.042_BIB6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00019501-199907000-00012","article-title":"Diabetes mellitus in older African-Americans, Hispanics, and whites in an academic hospital-based geriatrics practice","volume":"10","author":"Ness","year":"1999","journal-title":"Coron Artery Dis"},{"issue":"Suppl 3","key":"10.1016\/j.ahj.2004.03.042_BIB7","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/dmrr.289","article-title":"Diabetes trends in the USA","volume":"18","author":"Skyler","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ahj.2004.03.042_BIB8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.7326\/0003-4819-136-8-200204160-00005","article-title":"A diabetes report card for the United States","volume":"136","author":"Saaddine","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJMoa010273","article-title":"Characteristics of patients with uncontrolled hypertension in the United States","volume":"345","author":"Hyman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB10","doi-asserted-by":"crossref","unstructured":"The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997;157:2413\u201346","DOI":"10.1001\/archinte.1997.00440420033005"},{"issue":"Suppl 3","key":"10.1016\/j.ahj.2004.03.042_BIB11","first-page":"44","article-title":"Scope of cardiovascular complications in patients with kidney disease","volume":"12","author":"McCullough","year":"2002","journal-title":"Ethn Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2004.03.042_BIB12","first-page":"S2","article-title":"Beyond serum creatinine","volume":"4","author":"McCullough","year":"2003","journal-title":"Rev Cardiovasc Med"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2004.03.042_BIB13","first-page":"S46","article-title":"Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"2","year":"2002","journal-title":"Am J Kidney Disease"},{"key":"10.1016\/j.ahj.2004.03.042_BIB14","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ki.1996.481","article-title":"Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group","volume":"50","author":"Breyer","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2004.03.042_BIB15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1191\/1358863x02vm412ra","article-title":"Microalbuminuria","volume":"7","author":"Garg","year":"2002","journal-title":"Vasc Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB16","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s001250050618","article-title":"Glomerular hyperfiltration in microalbuminuric NIDDM patients","volume":"39","author":"Vedel","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2004.03.042_BIB17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archinte.160.8.1093","article-title":"The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus","volume":"160","author":"Valmadrid","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB18","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1001\/archinte.158.17.1933","article-title":"Microalbuminuria in nondiabetic adults","volume":"158","author":"Cirillo","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/0003-4819-133-8-200010170-00008","article-title":"Smoking is related to albuminuria and abnormal renal function in nondiabetic persons","volume":"133","author":"Pinto-Sietsma","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB20","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1046\/j.1523-1755.2002.00356.x","article-title":"Albuminuria and renal insufficiency prevalence guides population screening","volume":"61","author":"Garg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2004.03.042_BIB21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1056\/NEJM199505113321902","article-title":"Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus","volume":"332","author":"Krolewski","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.ki.4495353","article-title":"Serum homocysteine level and protein intake are related to risk of microalbuminuria","volume":"54","author":"Hoogeveen","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2004.03.042_BIB23","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1001\/archinte.158.18.2007","article-title":"Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men","volume":"158","author":"Lowe","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB24","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"issue":"6 Suppl 4","key":"10.1016\/j.ahj.2004.03.042_BIB25","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0272-6386(98)70159-3","article-title":"Trends in treatment and survival for hemodialysis patients in the United States","volume":"32","author":"Port","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2004.03.042_BIB26","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Viberti","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/BF00403380","article-title":"Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy","volume":"37","author":"Elving","year":"1994","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2004.03.042_BIB29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.03.042_BIB30","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/diab.43.9.1108","article-title":"Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy","volume":"43","author":"Nielsen","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2004.03.042_BIB31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0002-9343(99)80226-5","article-title":"The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group","volume":"99","author":"Laffel","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE)","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.03.042_BIB33","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.03.042_BIB34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0272-6386(00)70018-7","article-title":"Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease","volume":"35","author":"Kshirsagar","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2004.03.042_BIB35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB36","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB37","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB38","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1001\/archinte.161.12.1492","article-title":"Angiotensin II subtype 1 receptor blockers and renal function","volume":"161","author":"Toto","year":"2001","journal-title":"Arch Intern Med"},{"issue":"12 Suppl 1","key":"10.1016\/j.ahj.2004.03.042_BIB39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0026-0495(97)90314-0","article-title":"Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting","volume":"46","author":"Cathelineau","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.ahj.2004.03.042_BIB40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.03.042_BIB41","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archinte.158.9.998","article-title":"Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia","volume":"158","author":"Ravid","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1523-1755.2001.00487.x","article-title":"Effect of lipid reduction on the progression of renal disease","volume":"59","author":"Fried","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2004.03.042_BIB43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00041552-200203000-00001","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis","volume":"11","author":"Sica","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ahj.2004.03.042_BIB44","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.03.042_BIB45","first-page":"2981","article-title":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.03.042_BIB46","unstructured":"Rahman M, Cutler J, Davis B, et al. Cardiovascular disease (CVD) outcomes in hypertensive patients with impaired renal function [abstract]. National Kidney Foundation Clinical Meeting Speaker Papers & Abstracts, 2003. p. 225"},{"key":"10.1016\/j.ahj.2004.03.042_BIB47","unstructured":"Rahman M, Cutler J, Davis B, et al. Renal outcomes in hypertensive patients with impaired renal function [abstract]. National Kidney Foundation Clinical Meeting Speaker Papers & Abstracts, 2003. p. 226"},{"key":"10.1016\/j.ahj.2004.03.042_BIB48","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.03.042_BIB49","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.2337\/diacare.22.11.1802","article-title":"Glycemic control in diabetic American Indians","volume":"22","author":"Hu","year":"1999","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.ahj.2004.03.042_BIB50","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00005344-199800002-00006","article-title":"Diabetic hypertensive patients","volume":"31","author":"Makrilakis","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.ahj.2004.03.042_BIB51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ndt\/15.suppl_1.7","article-title":"AGEs and carbonyl stress","volume":"15","author":"Zoccali","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 77","key":"10.1016\/j.ahj.2004.03.042_BIB52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1523-1755.2000.07705.x","article-title":"The missing link","volume":"58","author":"Nishikawa","year":"2000","journal-title":"Kidney Int"},{"issue":"Suppl 76","key":"10.1016\/j.ahj.2004.03.042_BIB53","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1046\/j.1523-1755.2000.07615.x","article-title":"Relevance of oxidative and carbonyl stress to long-term uremic complications","volume":"58","author":"Miyata","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2004.03.042_BIB54","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0891-5849(00)00228-8","article-title":"Glycoxidation and lipoxidation in atherogenesis","volume":"28","author":"Baynes","year":"2000","journal-title":"Free Radic Biol Med"},{"issue":"Suppl 4","key":"10.1016\/j.ahj.2004.03.042_BIB55","first-page":"25","article-title":"Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions","volume":"26","author":"Zaoui","year":"2000","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ahj.2004.03.042_BIB56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/heart.85.1.87","article-title":"Increased serum concentrations of advanced glycation end products","volume":"85","author":"Kiuchi","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2004.03.042_BIB57","first-page":"1","article-title":"Chemistry and pathobiology of advanced glycation end products","volume":"131","author":"Schleicher","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.ahj.2004.03.042_BIB58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0006-2952(00)00318-X","article-title":"Improvement by aminoguanidine of insulin secretion from pancreatic islets grafted to syngeneic diabetic rats","volume":"60","author":"Hiramatsu","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ahj.2004.03.042_BIB59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0197-2456(99)00024-0","article-title":"Design and baseline characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II)","volume":"20","author":"Freedman","year":"1999","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ahj.2004.03.042_BIB60","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9343(97)00150-2","article-title":"Acute renal failure after coronary intervention","volume":"103","author":"McCullough","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB61","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.CIR.95.4.878","article-title":"Preoperative renal risk stratification","volume":"95","author":"Chertow","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.03.042_BIB62","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0735-1097(99)00608-7","article-title":"The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction","volume":"35","author":"Dries","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.03.042_BIB63","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0735-1097(00)00774-9","article-title":"Risks associated with renal dysfunction in coronary care unit patients","volume":"36","author":"McCullough","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.03.042_BIB64","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/01.CIR.0000016043.87291.33","article-title":"Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention","volume":"105","author":"Rihal","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.03.042_BIB65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2165\/00019053-199405010-00004","article-title":"Low-dosage epoetin in maintenance haemodialysis","volume":"5","author":"Harris","year":"1994","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2004.03.042_BIB66","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000045703","article-title":"Morbidity and mortality reduction associated with the use of erythropoietin","volume":"85","author":"Tsakiris","year":"2000","journal-title":"Nephron"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2004.03.042_BIB67","first-page":"S182","article-title":"clinical practice guidelines for anemia of chronic kidney disease","volume":"37","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2004.03.042_BIB68","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0197-2456(00)00062-3","article-title":"Design and statistical issues of the Hemodialysis (HEMO) study","volume":"21","author":"Greene","year":"2000","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ahj.2004.03.042_BIB69","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMoa021583","article-title":"Effect of dialysis dose and membrane flux in maintenance hemodialysis","volume":"347","author":"Eknoyan","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl 75","key":"10.1016\/j.ahj.2004.03.042_BIB70","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1046\/j.1523-1755.2000.07503.x","article-title":"The role of lipids in renal disease","volume":"57","author":"Keane","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2004.03.042_BIB71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/01.CIR.97.2.138","article-title":"Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease","volume":"97","author":"Moustapha","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.03.042_BIB72","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJMoa011364","article-title":"Decreased rate of coronary restenosis after lowering of plasma homocysteine levels","volume":"345","author":"Schnyder","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB73","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/jama.288.8.973","article-title":"Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous coronary intervention","volume":"288","author":"Schnyder","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.03.042_BIB74","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7326\/0003-4819-131-5-199909070-00008","article-title":"Homocyst(e)ine and cardiovascular disease","volume":"131","author":"Eikelboom","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2004.03.042_BIB75","first-page":"p.xxiii","article-title":"USRDS 1999 annual data report","year":"1999"},{"key":"10.1016\/j.ahj.2004.03.042_BIB76","first-page":"284","article-title":"Comparison of treatment costs between dialysis and transplantation","volume":"12","author":"Eggers","year":"1992","journal-title":"Semin Nephrol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870304001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870304001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:07:19Z","timestamp":1757567239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870304001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0002870304001991"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2004.03.042","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Slowing the progression of diabetic nephropathy and its cardiovascular consequences","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2004.03.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}